Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. As a heterogeneous disease, breast cancer requires a diverse and targeted therapeutic approach to improve patient outcomes. At Alfa Cytology, we specialize in the preclinical discovery of histone deacetylase (HDAC) inhibitors and promotes the development of new therapies for breast cancer.
Excessive HDAC activity has been strongly linked to the initiation and proliferation of breast tumors, making them an attractive target for therapeutic intervention. By targeting histone and several non-histone proteins, histone deacetylase inhibitors (HDACi) can maintain the cellular acetylation profile and reverse the function of several proteins responsible for breast cancer development.
Fig.1 The role of histone deacetylase inhibitors in metastatic breast cancer. (Zucchetti B., et al. 2019)
The field of HDAC inhibitor development for breast cancer treatment has witnessed remarkable progress in recent years. Extensive research has revealed the unique roles and expression patterns of individual HDAC isoforms in breast cancer biology. By selectively modulating the activity of specific HDAC classes, researchers have been able to develop more targeted and effective HDAC inhibitor therapies.
| NCT number | AR agent | Phase |
| NCT03444025 | Panobinostat (LBH589) | |
| NCT00719875 | Vorinostat | |
| NCT02833155 | Entinostat; Exemestane | |
| NCT03742245 | Olaparib; Vorinostat | |
| NCT01194908 | Decitabine; LBH589; Tamoxifen |
As a leading preclinical CRO, Alfa Cytology is committed to advancing the development of innovative cancer therapies, including novel HDAC inhibitor for breast cancer. Our state-of-the-art facilities and multidisciplinary team of experts provide comprehensive services to support the entire drug development process, from target identification and validation to preclinical studies and biomarker development.
Pan-HDAC Inhibitors Development
Pan-HDAC inhibitors target multiple HDAC isoforms (classes I, II, and IV) with varying degrees of potency.
Class-selective inhibitors target specific HDAC classes (e.g., class I, class II, or class IV) to achieve more selective modulation of gene expression.
Class-Selective HDAC Inhibitors Development
Isoform-Selective HDAC Inhibitors Development
Isoform-selective inhibitors target individual HDAC isoforms within a class to further refine the therapeutic approach.
Natural product-derived HDAC inhibitors are derived from natural sources, such as plants or microorganisms.
Natural Product-Derived HDAC Inhibitors Development
Alfa Cytology provides development services for HDAC inhibitors, covering drug design, screening, and efficacy research to find ideal drug candidates for you and accelerate preclinical research on your breast cancer therapeutics. To learn more about our capabilities in HDAC inhibitors development for breast cancer or to discuss potential collaborative opportunities, please don't hesitate to contact us.
Reference